| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Prenetics Global Limited$20.28
-0.23 (-1.12%)
F 10Pipeline Score Tools & Services · Clinical
Market Cap
298.37 M
EPS
-4.11
P/E Ratio
-4.31 $
Value Trade
5.06 M
12.14 %
Week
-19.65 %
1 Month
-42.12 %
3 Month
-59.22 %
6 Month
-96.51 %
5 Year
-47.72 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
35.26 K
52 Week Range
3.45 - 23.63
% held by Insiders
24.32 %
% held by Institutions
9.77 %
Enterprise Value
238.56 M
Total Shares
11.95 M
Short %
9.36 %
Float Shares
9.00 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 834 of 905)
Percentile RankPrenetics Global Limited has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Prenetics Global Limited (PRE) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRENYSE Content Update: NYSE Partner Reindustrialize Kicks Off Summit from Detroit
The NYSE provided a pre-market update highlighting key developments, including the Dow's potential record growth following a U.S.-Iran deal. Reindustrialize Co-founder Austin Bishop will discuss the Summit aimed at boosting America's industrial sector. Additionally, OpenLoop's new Launchpad solution promises to enhance virtual care compliance for brands.
Read more →PRENYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
AstraZeneca has celebrated its transfer to the NYSE, marking the largest transfer by market capitalization in the exchange's history. This event coincides with a positive market reaction following the May jobs report and a record close for the DOW. CEO Pascal Soriot and CFO Dr. Aradhana Sarin are set to discuss the company's future financial goals in a live interview.
Read more →PRENYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
Hinge Health's shares have surged by 72% since its IPO last year, reflecting strong market performance. CEO Daniel Perez is set to discuss the company's growth in an interview, highlighting the positive trajectory since going public. The NYSE continues to provide updates on market activities and IPO developments.
Read more →PREPrenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
Prenetics Global Limited (NASDAQ: PRE) reported preliminary Q1 2026 results, showcasing a significant revenue increase driven by its IM8 brand, which grew nearly 6x year-over-year. The company raised its full-year IM8 revenue guidance to between $190 million and $210 million. Despite a reported operational loss, the company anticipates continued growth with new product launches and strong international expansion.
Read more →PRENYSE Content Update: Global Medical Response to Go Public After $479 Million IPO
Global Medical Response is set to go public following a $479 million IPO. The company's CEO, Nick Loporcaro, will discuss future plans during its trading debut on the NYSE. The overall market sentiment appears positive, with equities rising after favorable economic reports.
Read more →PRENYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation
Eli Lilly is set to celebrate its 150th anniversary, marking a significant milestone in its history of scientific innovation. The company's CFO, Lucas Montarce, will participate in a discussion on NYSE Live to share insights from recent earnings and the company's journey. This celebration underscores Eli Lilly's enduring influence in the biopharma sector.
Read more →PREPrenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
Prenetics Global Limited will announce its Q1 2026 financial results on May 14, 2026, before market open. The earnings conference call will take place at 8:30 a.m. ET, featuring a Q&A session with analysts. The company highlights its successful IM8 brand, which has quickly gained traction in the consumer health market.
Read more →PRENYSE Content Update: HawkEye 360 Soars 31% in Trading Debut
HawkEye 360 made a strong debut on the NYSE, with shares rising 31% following its IPO. The pre-market update indicates a generally positive market sentiment, influenced by recent developments in Iran and a favorable jobs report. Enhanced CEO Maximilian Martin is set to celebrate the company's IPO performance later today.
Read more →PRENYSE Content Update: UiPath Celebrates Five-Year Listing Anniversary at NYSE
UiPath marks its five-year anniversary as a publicly listed company on the NYSE. The event includes discussions on market insights and the company's journey since its IPO. Other notable anniversaries include Suburban Propane's 30th listing anniversary. Overall, the market is experiencing positive momentum as investors respond to recent developments.
Read more →PRENYSE Content Update: Defense Tech Company AEVEX to Make Its Public Debut
The New York Stock Exchange (NYSE) provided a pre-market update highlighting positive market trends. Aevex is set to make its public debut, with CEO Roger Wells discussing the company's strategy. Additionally, Madison Air saw a notable increase in its stock price on its first trading day.
Read more →PRENYSE Content Update: OpenLoop Health Debuts At-Home Sleep Apnea Test with 98% Accuracy
OpenLoop Health has launched an at-home sleep apnea test with an impressive accuracy of 98%. This development marks a significant step in the company's expansion into sleep diagnostics, in collaboration with Happy Sleep. The announcement was made during a pre-market update by the NYSE, highlighting the company's innovative approach in healthcare.
Read more →PRENYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
The NYSE has issued a pre-market update indicating a rise in equities following news of a potential ceasefire with Iran. The exchange is collaborating with the HumanX AI conference in San Francisco, featuring discussions on transformative technologies. Notably, James Foster from Charles River Laboratories will speak at NYSE Live, while Olympic athlete Mikaela Shiffrin recently marked her successful season at the NYSE.
Read more →PREPrenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
Prenetics Global Limited has announced a multi-year partnership with NBA Champion Giannis Antetokounmpo, who becomes the first NBA athlete shareholder in a NASDAQ-listed health brand. This collaboration aims to leverage Giannis's extensive social media reach and align with IM8's growth strategy, which has seen rapid revenue growth since its launch. The partnership is expected to enhance IM8's market presence and credibility across various sports.
Read more →PRENYSE Content Update: Koppers to Ring Closing Bell for 20th Listing Anniversary
The New York Stock Exchange (NYSE) announced that Koppers will ring the closing bell to celebrate its 20th anniversary of being listed. This event coincides with a positive market trend, despite ongoing uncertainties in the Middle East. The NYSE also features discussions on agricultural innovations and AI applications in business.
Read more →PRENYSE Content Update: York Space Systems Shoots for the Stars with New Contract
The New York Stock Exchange (NYSE) provided a pre-market update highlighting key developments. York Space Systems' CEO will discuss a new commercial contract during the Taking Stock segment. Additionally, the Digital Health CEO Summit is taking place, featuring discussions among top executives in the digital health sector. Ingram Micro's CFO will also share insights on AI and automation.
Read more →PREPrenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation
Prenetics' IM8 has partnered with Superpower to create a unique system that combines clinical-grade supplementation with comprehensive blood testing. This partnership allows consumers to measure the efficacy of their supplements through a closed-loop system. IM8 subscribers can access Superpower's blood testing services at a significantly reduced price, promoting a proactive approach to health management.
Read more →PREPrenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
Prenetics Global Limited's executives have made a second consecutive round of open market purchases, investing approximately $1.3 million in shares. This follows a prior investment of about $1.45 million, bringing total personal investments to $2.75 million. CEO Danny Yeung emphasized the strong performance of the IM8 brand and the belief that the share price does not reflect the company's progress.
Read more →PREPrenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
Prenetics Global Limited has launched Daily Ultimate Essentials PRO, a new clinical-grade health supplement featuring enhanced potency and bioavailability. The reformulated product introduces two new flavors, Mango + Passionfruit and Lemon + Orange, while keeping the price unchanged for all customers. The PRO formula incorporates advanced nutritional science, including bioactive vitamin forms for superior absorption.
Read more →PREPrenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
Prenetics Global Limited reported record financial results for Q4 and FY 2025, driven by the success of its IM8 brand, which achieved $120 million in annual recurring revenue within just 12 months. The company's revenue surged by 480% year-over-year to $92.4 million. Strategic divestitures have improved liquidity, positioning Prenetics for continued growth, despite facing challenges such as increased costs and ongoing losses.
Read more →PREPrenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
Prenetics Global Limited has completed the sale of its 35% equity interest in Insighta to Tencent for $70 million. This transaction significantly boosts the company's liquidity, bringing total adjusted liquidity to $171.1 million. With zero debt, Prenetics aims to accelerate the global expansion of its IM8 brand, which has shown rapid growth in the consumer health sector.
Read more →PREFormula 1 Phenom Ollie Bearman Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
Prenetics Global Limited has announced Formula 1 driver Ollie Bearman as its new Global Ambassador and shareholder for its IM8 health brand. Bearman, who has shown impressive performance in his racing career, credits IM8's Daily Ultimate Essentials for enhancing his energy and recovery. This partnership underscores IM8's focus on aligning with elite athletes and its rapid growth in the health supplement market.
Read more →PREPrenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call
Prenetics Global Limited (NASDAQ: PRE) will announce its financial results for Q4 and the full year 2025 on February 18, 2026, before market open. An earnings conference call will follow at 10:00 a.m. ET, including a Q&A session. The company's IM8 brand has achieved significant growth in the health and nutrition sector.
Read more →PREPrenetics Provides Update on Voluntary Warrant Exchange Program, Reaching 86.7% Participation
Prenetics Global Limited has reported an 86.7% participation in its voluntary warrant exchange program, an increase from 83.4%. This exchange will reduce the total number of outstanding warrants and the potential dilution to shareholders. The company believes this move simplifies its capital structure and enhances the attractiveness of its shares.
Read more →PREPrenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8
Prenetics Global Limited has announced a strategic shift to focus exclusively on its IM8 brand, ceasing Bitcoin purchases to allocate resources towards this rapidly growing consumer health brand. IM8 has achieved significant revenue milestones, generating over $100 million in annualized recurring revenue within 11 months. The company aims to enhance its operations and expand internationally while maintaining a strong financial position.
Read more →PREPrenetics Announces Upcoming Conference Participation
Prenetics Global Limited announced its participation in two upcoming investor conferences. CEO Danny Yeung will engage in one-on-one meetings at The Benchmark Company's conference on December 4, 2025, and deliver a presentation at Sidoti's Year End Virtual Investor Conference on December 10, 2025. The company continues to demonstrate impressive growth through its IM8 brand.
Read more →PREPrenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
Prenetics Global Limited announced that its executive leadership team purchased approximately $1.45 million in common stock, demonstrating their confidence in the company's future. The purchases included shares by CEO Danny Yeung and other executives, reflecting a collective belief in the growth of Prenetics and its IM8 brand. The company is also pioneering a Bitcoin treasury strategy.
Read more →PRECantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth
Cantor Fitzgerald has maintained its Overweight rating on Prenetics, adjusting the price target to $31 from $32. The report highlights strong unit economics and a forecasted revenue of $217 million by FY2026 as the IM8 brand expands internationally. However, the adjustment reflects valuation model updates due to the planned divestment of the Europa business.
Read more →PREPrenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR[1] by December 2025, Fastest Supplement Brand Growth in Industry HistoryAPAC - EnglishAPAC - Traditional Chinese
Prenetics reported a remarkable 568% year-over-year revenue increase to $23.6 million in Q3 2025, driven by its IM8 brand, which is on track to achieve $120 million in annual recurring revenue by December 2025. The company also announced a successful $44 million equity offering, enhancing its financial position for aggressive growth. Despite a significant adjusted EBITDA loss, Prenetics is optimistic about reaching $300 million ARR by the end of 2026.
Read more →PREPrenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History
Prenetics Global Limited reported a remarkable 568% year-over-year revenue increase, totaling $23.6 million in Q3 2025. The company’s IM8 brand is on track to achieve $120 million in annual recurring revenue by December 2025, marking the fastest growth in the supplement industry. The company also boasts strong unit economics and a solid financial foundation following a recent equity offering.
Read more →PREPrenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call
Prenetics Global Limited announced it will release its financial results for Q3 2025 on November 10, 2025, before market open. The company will also host its first earnings conference call at 8:30 a.m. ET the same day, which will include a Q&A session. Prenetics is noted for its rapid growth in the health sciences sector, particularly with its IM8 brand.
Read more →PREPrenetics’ IM8 Achieves Record $9 Million in Revenue for October, Surpasses $108 Million in Annualized Recurring Revenue 11 Months After Launch
Prenetics Global Limited reported a record $9 million in revenue for October, marking a 32% month-over-month increase. The company achieved approximately $108 million in annualized recurring revenue just 11 months post-launch of its IM8 brand. With a recent $44 million equity offering, Prenetics is positioned for accelerated growth and global expansion, exploring partnerships with top athletes.
Read more →PREPrenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
Prenetics Global Limited has acquired 100 Bitcoin, increasing its total holdings to 378 BTC. This acquisition follows a successful $44 million equity offering, attracting notable investors. The company reported record growth for its IM8 supplement brand, achieving $100 million in annual recurring revenue within 11 months. Prenetics aims to leverage its strong financial position to accelerate growth and maintain market leadership.
Read more →PREPrenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth
Prenetics Global Limited, led by CEO Danny Yeung, has published a manifesto titled "The Dual-Engine Revolution," detailing its innovative strategy combining healthcare growth with Bitcoin treasury management. The company has achieved remarkable success with its IM8 supplement brand, reaching $100 million in annual recurring revenue within 11 months. The manifesto outlines the financial resilience provided by their Bitcoin strategy and the projected revenue growth for the upcoming fiscal year.
Read more →PREPrenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
Prenetics Global Limited has successfully closed a public equity offering, raising approximately $44 million. The funds will be utilized for the global expansion of its IM8 brand and for accumulating Bitcoin as part of its dual health and wealth strategy. The company has experienced rapid growth, achieving significant revenue milestones within a short period.
Read more →PREPrenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
Prenetics announced an oversubscribed equity offering, raising approximately $48 million, with potential total proceeds of $216 million. The offering is aimed at fueling the global expansion of its supplement brand, IM8, which has rapidly achieved $100 million in annual recurring revenue. The company is also focusing on its Bitcoin treasury strategy, aiming for significant growth in the coming years.
Read more →PREPrenetics Global Limited Announces Proposed Public Offering
Prenetics Global Limited has announced a public offering of its Class A Ordinary Shares and common warrants to support the global expansion of its IM8 brand and to accumulate Bitcoin as part of its innovative strategy. The offering is contingent on market conditions, and details will be filed with the SEC. Prenetics is recognized for its rapid growth in the health sciences sector and its unique position in the cryptocurrency space.
Read more →PREPrenetics’ IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging
Prenetics Global Limited has launched Daily Ultimate Longevity, the first supplement targeting all 12 hallmarks of aging. This product, part of the IM8 Health brand co-founded by David Beckham, has seen rapid growth, achieving $6.6 million in monthly revenue. The supplement features a proprietary 5-Complex System developed with leading scientists, aiming to redefine longevity science.
Read more →PREPrenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year's EndAPAC - EnglishAPAC - Traditional Chinese
Prenetics reported impressive financial results for Q2 2025, with a 452.1% increase in revenue year-over-year, reaching $32.3 million. The company anticipates its IM8 brand will achieve $100 million in annual recurring revenue by year-end. Additionally, Prenetics plans to reach break-even by Q1 2026, supported by a robust Bitcoin treasury strategy.
Read more →PREPrenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 GuidanceAPAC - EnglishAPAC - Traditional Chinese
Prenetics Global Limited reported a significant revenue growth of 93.5% in Q4 2024, totaling $10.5 million, and a year-over-year increase of 40.9% to $30.6 million for the full year. The company projects a revenue of $73 million to $85 million for 2025, driven by the launch of its IM8 Health brand. CEO Danny Yeung highlighted the company's strategic focus on consumer health brands and the positive impact of recent acquisitions.
Read more →PREPrenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium SupplementsAPAC - EnglishAPAC - Traditional Chinese
Prenetics' IM8 has announced a collaboration with Mayo Clinic to develop a new line of premium supplements. This partnership aims to create evidence-based products focusing on nutrition, cellular rejuvenation, and overall wellness. The collaboration combines IM8's innovation with Mayo Clinic's medical expertise, ensuring high standards of efficacy. Initial research is already yielding promising results.
Read more →PREPrenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications ServicesAPAC - EnglishAPAC - Traditional Chinese
Prenetics' IM8 has launched a month-long space experiment aboard the ISS, in collaboration with the University of Oxford. The study aims to investigate accelerated aging and longevity by utilizing microgravity to mimic aging processes at the cellular level. This research could lead to significant advancements in understanding age-related diseases and improving healthspan on Earth.
Read more →Competitive Position
How PRE ranks across every disease it competes inCompetitive Position is a premium feature
See how PRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial